Belite Bio announces successful Phase 1 clinical trials of AMD drug
Category: #health  By Saipriya Iyer  Date: 2020-07-21
  • share
  • Twitter
  • Facebook
  • LinkedIn

Belite Bio announces successful Phase 1 clinical trials of AMD drug

San Diego-based clinical stage biopharmaceutical firm, Belite Bio has recently revealed positive data from Phase 1 trials conducted in Australia and the U.S. on LBS-008, an oral small molecule RBP4 (Retinol Binding Protein 4) specific antagonist that is targeted towards treating atrophic Dry AMD (age-related macular degeneration) and its inherited juvenile form, Stargardt disease.

Sources close to the development state that around 83 subjects took part in the trials, with LBS-008 being administered either as a single or repetitive dose for two weeks. Following the clinical trials, it was established that doses of LBS-008 were proven to be well tolerated, with LBS-008's PK / PD profile supporting daily oral administration. In addition to this, LBS-008 attained possible clinical-level target engagement.

Dr. Konstantin Petrukhin, Prof. of Ophthalmic Science, Columbia University, said that the positive results from LBS-008 trial is given to an effective collaboration between Belite Bio, NIH, and the Columbia University. We are thrilled to see LBS-008 enter the next clinical phase and expect it to pause the progression of Stargardt disease and Dry AMD.

Charles Cywin, Program Director, National Institute of Neurological Disorders & Stroke, NIH, said that Dry AMD is one of the common causes of blindness and currently has no treatment. The LBS-008 clinical trial’s transition to Phase 2 comes as an example of how NIH BPN visions to help researchers transform promising ideas into effective therapies for addressing some of the most complex neurological disorders.  

As per Dr. Tom Lin, Chief Executive Officer, Belite Bio, their firm is pleased to have accomplished this key milestone along with the support of NIH BPN. The company appreciates the support of the BPN team for driving the development of LBS-008 in Phase 1 which has successfully demonstrated promising results.

Source Credit: https://www.prnewswire.com/news-releases/belite-bio-announces-positive-results-from-phase-1-clinical-trials-of-lbs-008-301095197.html



About Author

Saipriya Iyer

Email: [email protected]   

Saipriya Iyer

Saipriya Iyer develops content for Market Size Forecasters, Algosonline, and myriad other platforms. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her bel...

Read More

More News By Saipriya Iyer

Montero inks agreement to acquire Isabella Gold Silver Project
Montero inks agreement to acquire Isabella Gold Silver Project
By Saipriya Iyer

Montero Mining and Exploration Ltd. has reportedly inked a Binding Purchase & Sale Agreement to acquire a 100% or full interest in a private company in Chile. ChileCo holds several mineral rights to exploration cla...

PharmaCyte to submit IND application to FDA for clinical trial in LAPC
PharmaCyte to submit IND application to FDA for clinical trial in LAPC
By Saipriya Iyer

PharmaCyte Biotech, a clinical-stage biotechnology company, is reportedly set to submit an IND (Investigational New Drug) application to the U.S. FDA. The IND application is related to the Phase 2b clinical trial among...

Immunic announces topline data from Phase 2 EMPhASIS, IMU-838 trial
Immunic announces topline data from Phase 2 EMPhASIS, IMU-838 trial
By Saipriya Iyer

Immunic, Inc. has recently announced positive topline results from the Phase 2 EMPhASIS trial of IMU-838, in patients with RRMS (relapsing-remitting multiple sclerosis). IMU-838 is a next-generation, orally available s...